Exelixis gains $12m upfront in Merck PI3K-delta deal
This article was originally published in Scrip
Executive Summary
Exelixis has granted Merck & Co exclusive, worldwide rights to its preclinical PI3K-delta R&D programme – giving the biotech cancer developer the resources to move forward on its high-stakes late-stage development programme for lead compound carbozantinib, a potential treatment for medullary thyroid and prostate cancers.